Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Relay Therapeutics said its mutant-selective PI3K inhibitor zovega delivered 11 months of PFS in second-line HR-positive, HER2-negative breast cancer, versus 5.5 months for capivasertib. Management said the Phase III trial is ongoing and expects to guide on full enrollment later this year, with enrollment described as going well. The update is constructive for the pipeline but is still clinical-stage and not yet a commercialization event.

Analysis

The market is likely underappreciating how much of Relay’s valuation is now hostage to execution, not science. In a crowded PI3K class, a credible progression from “encouraging signal” to “registrational standard” depends on enrollment speed, durability of benefit, and whether safety stays clean enough to preserve real-world adoption versus a better-known incumbent. If management can keep the trial on schedule and repeatedly de-risk the dataset over the next 6-12 months, the stock can re-rate on a pathway-to-approval story long before Phase III readout.

The second-order dynamic is that any meaningful clinical win here would pressure the broader breast-cancer targeted-therapy complex, especially names whose implied durability assumes only modest competition. That matters because a differentiated mutation-selective profile can win share not just on efficacy, but on sequencing convenience and physician willingness to switch earlier in the treatment line. Conversely, if enrollment slips or tolerability turns out to be dose-limiting in practice, the market will likely compress the program back into a binary pipeline asset, which is a very different multiple regime.

The key contrarian view is that consensus may be too focused on headline PFS versus an existing benchmark and not enough on the commercial bar for adoption. In this class, a few months of nominal PFS advantage is not enough unless it translates into clean discontinuation rates, manageable dose modifications, and a compelling label that supports payer uptake. The setup is therefore asymmetric over the next 1-2 quarters: positive operational updates can drive sentiment quickly, while negative surprises would likely hit harder because expectations are already anchored to a high-quality execution narrative.

Key Decisions for Investors

• Long RLAY into the next enrollment update / protocol milestone, with a 3-6 month horizon; upside is a multiple expansion on de-risking, while downside is mostly limited to execution slippage rather than immediate trial failure.
• Buy RLAY call spreads out 6-12 months to express a favorable readout trajectory while capping premium burn; best risk/reward if you expect frequent positive operational updates before data.
• Pair trade: long RLAY / short a basket of late-line breast cancer incumbents or broader oncology platform names with crowded expectations, targeting relative outperformance if Relay proves cleaner differentiation.
• Trim or hedge if management commentary shifts from enrollment cadence to site expansion or amendment language; that is often the earliest tell that timelines are slipping by 1-2 quarters.
• For event-driven accounts, wait for the next concrete catalyst rather than chasing on conference tone alone; the stock can stay narrative-driven, but the real inflection is when operational milestones confirm the Phase III path.